455 — Tianda Pharmaceuticals Cashflow Statement
0.000.00%
- HK$387.01m
- HK$428.59m
- HK$329.94m
Annual cashflow statement for Tianda Pharmaceuticals, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | — |
Source: | ARS | ARS | ARS | ARS | |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | 15.9 | -27.4 | -28 | -25.7 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -5.38 | -3.96 | -11.3 | 2.08 | — |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -50 | -26.8 | 8.91 | -62.5 | — |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -19.9 | -37.6 | -8.23 | -49.8 | — |
Capital Expenditures | -102 | -146 | -46.5 | -65.9 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 61.3 | 8.72 | 133 | -3.2 | — |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -41.1 | -138 | 86.3 | -69.1 | — |
Financing Cash Flow Items | -14.5 | -6.94 | -0.887 | -25.2 | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.812 | 90.8 | -1.29 | -57.4 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -81.2 | -63.7 | 85.8 | -178 | — |